Compare YMT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | MIST |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 176.3M |
| IPO Year | 2025 | N/A |
| Metric | YMT | MIST |
|---|---|---|
| Price | $1.04 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 356.8K | ★ 2.1M |
| Earning Date | 06-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,502,945.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $0.63 |
| 52 Week High | $6.05 | $3.06 |
| Indicator | YMT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 34.51 |
| Support Level | $0.85 | $1.70 |
| Resistance Level | $1.84 | $1.89 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 21.11 | 2.86 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).